ITCI — Intra-Cellular Therapies Share News
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
J&J to buy Intra-Cellular Therapies for $14.6 billion (updated)
J&J to buy Intra-Cellular Therapies for $14.6 billion
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports (updated)
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
Brief: Johnson & Johnson Is Exploring Bid For Intra-Cellular Therapies - Bloomberg News
Brief: Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial (updated)
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Brief: Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention
U.S. RESEARCH ROUNDUP-Amazon, Chevron, Mastercard
U.S. RESEARCH ROUNDUP-Allstate, Brinker International, Meta
Intra-Cellular Therapies Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Intra-Cellular Therapies Q3 Net Income USD -26.3 Million
U.S. RESEARCH ROUNDUP- Broadcom, Costco Wholesale, Saia
U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake
Intra-Cellular Therapies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Intra-Cellular Therapies Q2 Net Income USD -16.2 Million
Intra-Cellular Therapies Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-CME Group, Ingersoll Rand, Winnebago Industries